BBNX earnings call summary

Prepared Highlights

• Q2 2025 net sales of $23.2M, up 54% YoY (CEO, CFO, prepared).
• New patient starts of 4,934 in Q2, up 57% YoY; ~71% of new starts came from prior multiple daily injection users (CFO, prepared).
• Pharmacy channel accounted for a high-20s percentage of new patient starts in Q2, up from mid-single-digit in Q2 2024 and low-20s in Q1 2025 (CEO, CFO, prepared).
• Gross margin of 53.8% in Q2, up slightly from 53.7% in Q2 2024 (CEO, CFO, prepared).
• Operating expenses of $32.4M in Q2, up 63% YoY from $19.9M (CFO, prepared).
• Cash and investments of ~$281M as of June 30, 2025 (CFO, prepared).
• RPO/backlog: Not explicitly stated.
• Full-year 2025 guidance raised: Net sales $88M–$93M (prior $82M–$87M); pharmacy mix 25%–28% of new patient starts (prior 22%–25%); gross margin 52%–55% (prior 50%–53%) (CFO, prepared).
• Q3/Q4 cadence: Revenue expected slightly higher Q3 vs Q2, and higher Q4 vs Q3; new patient starts similar Q3 vs Q2, higher Q4 vs Q3; pharmacy mix expected to increase in H2 but at a slower rate (CFO, prepared).
• CMS proposal: Proposed competitive bidding and pay-as-you-go rental model for Medicare fee-for-service insulin pumps; Beta Bionics expects no material revenue impact from competitive bidding, and sees pay-as-you-go as a net tailwind (CEO, prepared).

Mgmt Quotes

• “We delivered $23.2 million in net sales, which grew 54% year-over-year.” (CEO)
• “We now project that net sales for the full year of 2025 will be $88 million to $93 million, up from our prior guidance of $82 million to $87 million.” (CFO)
• “We believe the iLet is the only pump in the market that’s capable of producing those results across such a wide range of users and clinicians.” (CEO)
• “We are raising guidance across the board.” (CFO)
• “We’re building the most innovative pipeline in the industry with the aim of disrupting the industry and ourselves.” (CEO)

Prepared Metrics

Q&A Batch (1-5 of 8)

Q1 — Matthew Oliver O'Brien

• Topic: Pharmacy channel ASP and churn rate
• Key points:
  • iLet pharmacy ASP declined due to more PBM adoption; rebates issued when PBMs are involved, lowering ASP.
  • Pharmacy supply kit ASP unchanged Q1→Q2; Q2 had a stocking headwind vs Q1.
  • Churn rate not disclosed; mgmt stated pharmacy channel is the most advantaged financially, so all eligible patients are sent there.
• Mgmt stance: Neutral — explained ASP dynamics as a sign of success in pharmacy adoption, but declined to provide churn numbers.

Q2 — Stephanie Laura Piazzola

• Topic: 2025 guidance raise and CMS proposal
• Key points:
  • Q2 beat by ~$4M; guidance raised by $6M at midpoint.
  • Q3 new patient starts guided flat vs Q2 due to: (1) seasonal Q2/Q3 neutrality, (2) Q2 was a very strong quarter, (3) guidance set at a highly confident level.
  • CMS home health proposal: comments due by end of Aug/early Sep; earliest implementation expected 2027.
• Mgmt stance: Bullish — high confidence in all guidance; CMS proposal timeline is speculative but earliest is 2027.

Q3 — Michael K. Polark

• Topic: New patient start drivers and Medicare proposal risk
• Key points:
  • Sequential growth in starts driven by both increased penetration with existing prescribers and new prescriber sign-ups; field sales team expanded vs last year.
  • CMS pay-as-you-go proposal: no mention of commercial DME or Medicare Advantage risk; Beta Bionics already uses a pay-as-you-go model in pharmacy.
  • Mgmt added: company is proactively insulating itself from any future pay-as-you-go shift.
• Mgmt stance: Neutral — declined to quantify prescriber dynamics; sees no risk from CMS proposal to commercial plans, and is preparing for potential changes.

Q4 — Unidentified Analyst

• Topic: Type 2 off-label use and revenue visibility
• Key points:
  • Type 2 patients are a stronger contributor as a percentage of new patient starts; iLet is off-label for type 2.
  • Physicians prescribe off-label as they see fit; mgmt kept comments general.
  • Recurring revenue from pharmacy installed base makes revenue more predictable; flat new patient starts still drive sequential revenue growth.
  • CMS pay-as-you-go and competitive bidding: mgmt expects both to be implemented together, earliest 2027.
• Mgmt stance: Neutral — acknowledged type 2 strength but avoided specifics due to off-label status; bullish on recurring revenue visibility.

Q5 — Frank James Takkinen

• Topic: Type 2 adoption channels and sales force hiring
• Key points:
  • iLet adoption for type 2 patients occurs in both primary care and endo channels, similar to type 1.
  • Sales force: started year with 43 territories, ended Q1 with 63, ended Q2 still at 63; no major expansion expected for remainder of 2025, likely early 2026.
• Mgmt stance: Neutral — cautious on type 2 commentary due to off-label; neutral on sales force, with expansion deferred to next year.

Q&A Batch (6-8 of 8)

Q6 — Jeffrey D. Johnson

• Topic: Pharmacy channel mix and Prime contract dynamics; Medicare Part D competitive bidding
• Key points:
  • Prime contract achieved both PBM agreement and underlying health plan coverage simultaneously; other PBM agreements (e.g., large one effective July 1) require separate health plan sales cycles after step 1.
  • Historical sequential pharmacy adoption uptick driven by both Prime deal and continued layering of underlying plans from other PBMs.
  • CMS proposal mentions pay-as-you-go model but does not mention Part B, insulin pumps, or patch pumps (Part D treatment); no reason to believe it insinuates anything about patch pumps or Part D insulin delivery devices.
• Mgmt stance: Neutral — Stephen Feider declines to predict timeline for durable pumps moving to Part D; Sean Saint notes pay-as-you-go model may blur durable vs. disposable distinction but says “we’ll have to wait and see.”

Q7 — Felipe Raul Lamar

• Topic: New patient start drivers and gross margin guidance
• Key points:
  • Two reasons for new patient start uptick: (1) iLet’s differentiated simplicity and clinical results resonating with doctors; (2) pharmacy coverage dramatically reduces out-of-pocket vs. DME, creating a tailwind for new starts (including switches from other durable pumps without 4-year warranty lock-in).
  • Gross margin guidance raised despite pharmacy headwind due to continued benefit from lower cost per unit with scale; strong confidence in cost per unit for remainder of year.
• Mgmt stance: Bullish — Stephen Feider cites clear drivers for new patient starts and cost improvements supporting margin expansion.

Q8 — Jeffrey Scott Cohen

• Topic: OpEx outlook for H2 2025 and R&D lumpiness
• Key points:
  • G&A and sales & marketing expenses: no big uptick expected in Q3 and Q4; leverage expected to increase.
  • R&D: may see uptick in Q3 and Q4 associated with Mint program and bihormonal project.
  • Over next 2–6 quarters, R&D expected to be lumpy.
• Mgmt stance: Neutral — Stephen Feider confirms R&D lumpiness due to specific projects, while signaling OpEx leverage in sales/marketing and G&A.